Artiva: De-Risking RA Opportunity With AlloNK and Fast-Track Path Supports Buy Rating

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ARTV stock, giving a Buy rating yesterday.

Emily Bodnar has given his Buy rating due to a combination of factors tied to Artiva’s lead program AlloNK plus rituximab in refractory rheumatoid arthritis and the upcoming clinical catalysts. He views the company’s 1H26 readout in at least 15 patients with roughly six months of follow-up as a pivotal de‑risking event, with a 50% ACR50 target that would markedly exceed response rates typically seen in late‑line RA, yet remains scientifically attainable given the mechanism of action.

Bodnar also highlights the differentiated safety and outpatient profile of AlloNK compared with both allogeneic and autologous CD19 CAR‑T competitors, supporting broader real‑world uptake if efficacy is confirmed. In addition, he anticipates a registration‑oriented RA trial design to be clarified in 1H26, potentially using a streamlined single‑arm approach, aided by FDA Fast Track status that underscores the unmet need and could shorten the path to approval, collectively supporting an attractive risk‑reward for ARTV shares.

Bodnar covers the Healthcare sector, focusing on stocks such as NovoCure, Agios Pharma, and TG Therapeutics. According to TipRanks, Bodnar has an average return of 6.4% and a 35.07% success rate on recommended stocks.